

**Clinical trial results:****A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers****Summary**

EudraCT number	2014-002565-30
Trial protocol	FI ES CZ HU NL DK DE GB
Global end of trial date	21 February 2020

**Results information**

Result version number	v1 (current)
This version publication date	
First version publication date	

**Trial information****Trial identification**

Sponsor protocol code	M14-359
-----------------------	---------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02264990
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	AbbVie
Sponsor organisation address	AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6-4UB
Public contact	Global Medical Services, AbbVie, 001 800-633-9110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a>
Scientific contact	Global Medical Services, AbbVie, 001 800-633-9110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a>

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 February 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	21 February 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.

Protection of trial subjects:

Subject read and understood the information provided about the study and gave written permission.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 September 2014
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	48 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 6
Country: Number of subjects enrolled	Australia: 19
Country: Number of subjects enrolled	Canada: 12
Country: Number of subjects enrolled	Israel: 14
Country: Number of subjects enrolled	Japan: 72
Country: Number of subjects enrolled	Korea, Republic of: 19
Country: Number of subjects enrolled	New Zealand: 11
Country: Number of subjects enrolled	Russian Federation: 74
Country: Number of subjects enrolled	South Africa: 19
Country: Number of subjects enrolled	Taiwan: 14
Country: Number of subjects enrolled	Turkey: 27
Country: Number of subjects enrolled	United States: 97
Country: Number of subjects enrolled	Czechia: 7
Country: Number of subjects enrolled	Denmark: 7
Country: Number of subjects enrolled	Finland: 3
Country: Number of subjects enrolled	Germany: 13
Country: Number of subjects enrolled	Hungary: 34
Country: Number of subjects enrolled	Netherlands: 31
Country: Number of subjects enrolled	Spain: 54
Country: Number of subjects enrolled	United Kingdom: 62

Worldwide total number of subjects	595
EEA total number of subjects	149

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	316
From 65 to 84 years	278
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled at 131 sites in 20 countries (Argentina, Australia, Canada, Czech Republic, Denmark, Finland, Germany, Hungary, Israel, Japan, South Korea, Netherlands, New Zealand, Russian Federation, South Africa, Spain, Taiwan, Turkey, United Kingdom, and United States).

### Pre-assignment

Screening details:

Participants were randomized in a 1:1 ratio to veliparib plus carboplatin and paclitaxel (C/P) or investigator's choice of platinum doublet chemotherapy. Randomization was stratified by smoking status (current vs former), investigators' preferred doublet therapy (C/P vs cisplatin/pemetrexed vs carboplatin/pemetrexed), gender, and ECOG PS (0 vs 1).

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Investigator's Choice Chemotherapy

Arm description:

Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:

- Carboplatin at an area under the curve (AUC) of 6 mg/mL\*min + paclitaxel 200 mg/m<sup>2</sup>

- Cisplatin 75 mg/m<sup>2</sup> + pemetrexed 500 mg/m<sup>2</sup>

- Carboplatin AUC 6 or AUC 5 mg/mL\*min + pemetrexed 500 mg/m<sup>2</sup>

After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m<sup>2</sup> on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.

Arm type	Active comparator
Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Administered at an AUC 6 mg/mL\*min or AUC 5 mg/mL\*min on Day 1 of each 21-day cycle.

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Administered by intravenous infusion 200 mg/m<sup>2</sup> on Day 1 of each 21-day cycle.

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Administered by intravenous infusion at 75 mg/m<sup>2</sup> on Day 1 of each 21-day cycle.

Investigational medicinal product name	Pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for infusion, Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Administered by intravenous infusion at 500 mg/m <sup>2</sup> Day 1 of each 21-day cycle	
<b>Arm title</b>	Veliparib + Carboplatin + Paclitaxel

Arm description:

Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\*min on Day 1 and paclitaxel 200 mg/m<sup>2</sup> on Day 1 of each 21-day cycle for a maximum of 6 cycles.

After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m<sup>2</sup> on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.

Arm type	Experimental
Investigational medicinal product name	Veliparib
Investigational medicinal product code	ABT-888
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

120 mg orally twice a day on Days -2 to 5 of each 21-day cycle.

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Administered at an AUC 6 mg/mL\*min on Day 1 of each 21-day cycle.

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Administered by intravenous infusion at 200 mg/m<sup>2</sup> on Day 1 of each 21-day cycle.

Number of subjects in period 1	Investigator's Choice Chemotherapy	Veliparib + Carboplatin + Paclitaxel
Started	297	298
Received Treatment	288	293
Received Maintenance Therapy	148	123
Completed	37	39
Not completed	260	259
Death	255	250
Other	-	1
Consent withdrawn by subject	4	5

Lost to follow-up	1	3
-------------------	---	---

## Baseline characteristics

### Reporting groups

Reporting group title	Investigator's Choice Chemotherapy
-----------------------	------------------------------------

Reporting group description:

Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:

- Carboplatin at an area under the curve (AUC) of 6 mg/mL\*min + paclitaxel 200 mg/m<sup>2</sup>
- Cisplatin 75 mg/m<sup>2</sup> + pemetrexed 500 mg/m<sup>2</sup>
- Carboplatin AUC 6 or AUC 5 mg/mL\*min + pemetrexed 500 mg/m<sup>2</sup>

After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m<sup>2</sup> on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.

Reporting group title	Veliparib + Carboplatin + Paclitaxel
-----------------------	--------------------------------------

Reporting group description:

Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\*min on Day 1 and paclitaxel 200 mg/m<sup>2</sup> on Day 1 of each 21-day cycle for a maximum of 6 cycles.

After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m<sup>2</sup> on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.

Reporting group values	Investigator's Choice Chemotherapy	Veliparib + Carboplatin + Paclitaxel	Total
Number of subjects	297	298	595
Age categorical			
Units: Subjects			
< 65 years	153	163	316
≥ 65 years	144	135	279
Age continuous			
Units: years			
arithmetic mean	63.1	62.7	-
standard deviation	± 8.99	± 9.02	
Gender categorical			
Units: Subjects			
Female	90	92	182
Male	207	206	413
Race			
Units: Subjects			
White	233	229	462
Black	11	11	22
Asian	53	57	110
Other	0	1	1
Ethnicity			
Units: Subjects			
Hispanic or Latino	22	26	48
Not Hispanic or Latino	275	272	547
Region			
Units: Subjects			
US and Western EU and Australia and Canada	177	157	334
Eastern EU/Russia	68	88	156

Japan	37	35	72
Other Asia	15	18	33
Smoking Status			
Units: Subjects			
Current smoker	153	152	305
Past smoker	144	146	290
Investigators' Preferred Platinum Doublet Therapy			
The investigator's preferred choice of platinum doublet therapy prior to randomization, which was used as a stratification factor. Note that while the investigator's pre-randomization preferred choice for the doublet is summarized, all participants on the veliparib arm received carboplatin and paclitaxel as chemotherapy.			
Units: Subjects			
Carboplatin/paclitaxel	71	70	141
Cisplatin/pemetrexed	95	100	195
Carboplatin/pemetrexed	131	128	259
Eastern Cooperative Oncology Group (ECOG) Performance Status			
ECOG performance status is used by doctors and researchers to assess how a participant's disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. 0 = Fully Active; 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, No self-care			
Units: Subjects			
Grade 0 (Fully active)	113	116	229
Grade 1 (restricted but ambulatory)	184	182	366
Lung Subtype Panel (LSP) Assay Results			
LSP positive: Patients with tumors classified as positive for the gene expression-based lung subtype panel (LSP) biomarker LSP negative: Patients with tumors classified as negative for the gene expression-based lung subtype panel (LSP) biomarker			
Units: Subjects			
Not enough sample for LSP status evaluation	138	126	264
Sample QC failed	66	58	124
LSP positive	40	40	80
LSP negative	53	74	127



## End points

### End points reporting groups

Reporting group title	Investigator's Choice Chemotherapy
-----------------------	------------------------------------

Reporting group description:

Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:

- Carboplatin at an area under the curve (AUC) of 6 mg/mL\*min + paclitaxel 200 mg/m<sup>2</sup>
- Cisplatin 75 mg/m<sup>2</sup> + pemetrexed 500 mg/m<sup>2</sup>
- Carboplatin AUC 6 or AUC 5 mg/mL\*min + pemetrexed 500 mg/m<sup>2</sup>

After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m<sup>2</sup> on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.

Reporting group title	Veliparib + Carboplatin + Paclitaxel
-----------------------	--------------------------------------

Reporting group description:

Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\*min on Day 1 and paclitaxel 200 mg/m<sup>2</sup> on Day 1 of each 21-day cycle for a maximum of 6 cycles.

After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m<sup>2</sup> on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.

### Primary: Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup

End point title	Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup
-----------------	---

End point description:

Overall survival is defined as the time from the date that the participant was randomized to the date of the participant's death. OS was estimated using Kaplan-Meier methodology. Participants still alive at the data cut-off date were censored at the date they were last known to be alive.

End point type	Primary
----------------	---------

End point timeframe:

From randomization up to the data cut-off date of 15 July 2019; the median follow-up time was 44.5 and 45.3 months in LSP+ participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.

End point values	Investigator's Choice Chemotherapy	Veliparib + Carboplatin + Paclitaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40 <sup>[1]</sup>	40 <sup>[2]</sup>		
Units: months				
median (confidence interval 95%)	9.2 (5.1 to 11.7)	11.2 (7.5 to 15.8)		

Notes:

[1] - LSP-positive subgroup

[2] - LSP-positive subgroup

### Statistical analyses

Statistical analysis title	Primary Analysis of OS in the LSP+ Subgroup
Comparison groups	Investigator's Choice Chemotherapy v Veliparib + Carboplatin + Paclitaxel

Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority <sup>[3]</sup>
P-value	= 0.113 <sup>[4]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.644
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.396
upper limit	1.048

Notes:

[3] - A fixed sequence testing procedure was used for analyses of the primary and secondary efficacy endpoints to control for the familywise error rate. If veliparib plus C/P treatment was not statistically significantly better compared to the investigators' choice of standard therapy for the primary efficacy endpoint of OS in LSP+ participants, then statistical significance would not be declared for any of the secondary efficacy endpoints.

[4] - Log rank test stratified by ECOG performance status, investigators' preferred platinum therapy, and gender.

Statistical significance was determined by a two-sided P value  $\leq 0.05$ .

### Secondary: Progression Free Survival (PFS) in the Lung Subtype Panel Positive Subgroup

End point title	Progression Free Survival (PFS) in the Lung Subtype Panel Positive Subgroup
-----------------	---

End point description:

Progression-free survival is defined as the time from the date of randomization to the date of disease progression (PD) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death (all causes of mortality), whichever occurred first.

PD: At least a 20% increase in the size of target lesions, taking as reference the smallest size recorded since the treatment started (Baseline or after) with an absolute increase of at least 5 mm, the appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.

PFS was estimated using Kaplan-Meier methodology. Participants who did not have an event of disease progression or had not died on or before the cut-off date were censored at the date of their last disease progression assessment on or before the cut-off date. Any PD and death occurring > 26 weeks and > 12 weeks after the previous assessment, respectively, were excluded and patients were censored at last assessment before PD or death.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up to the data cut-off date of 15 July 2019; the median follow-up time was 44.5 and 45.3 months in LSP+ participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.

End point values	Investigator's Choice Chemotherapy	Veliparib + Carboplatin + Paclitaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40 <sup>[5]</sup>	40 <sup>[6]</sup>		
Units: months				
median (confidence interval 95%)	5.2 (2.8 to 6.2)	6.3 (3.5 to 7.4)		

Notes:

[5] - Lung subtype panel positive subgroup

[6] - Lung subtype panel positive subgroup

## Statistical analyses

<b>Statistical analysis title</b>	Analysis of PFS in LSP+ Subgroup
Comparison groups	Investigator's Choice Chemotherapy v Veliparib + Carboplatin + Paclitaxel
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	other <sup>[7]</sup>
P-value	= 0.26 <sup>[8]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.647
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.388
upper limit	1.08

Notes:

[7] - A fixed sequence testing procedure was used for analyses of the primary and secondary efficacy endpoints to control for the familywise error rate. If veliparib plus C/P treatment was not statistically significantly better than the investigators' choice of standard therapy for the primary efficacy endpoint of OS in LSP+ subjects, then statistical significance will not be declared for any of the secondary efficacy endpoints.

[8] - Log-rank test stratified by investigator's preferred platinum therapy, gender, and ECOG performance status.

### Secondary: Objective Response Rate (ORR) in the Lung Subtype Panel Positive Subgroup

End point title	Objective Response Rate (ORR) in the Lung Subtype Panel Positive Subgroup
-----------------	---

End point description:

Objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria. Response must have been confirmed at a consecutive assessment 28 days or more after the assessment at which response was first observed.

CR: The disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters, persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, or any new lesions.

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed on Day 1 of Cycles 3 and 5 then every 9 weeks for 1 year or until maintenance therapy was discontinued, then every 12 weeks until radiographic progression or death; median time on follow-up was 5.2 and 6.3 months in each group, respectively.

End point values	Investigator's Choice Chemotherapy	Veliparib + Carboplatin + Paclitaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40 <sup>[9]</sup>	40 <sup>[10]</sup>		
Units: percentage of participants				
number (confidence interval 95%)	30.0 (16.6 to 46.5)	22.5 (10.8 to 38.5)		

Notes:

[9] - Lung subtype panel positive subgroup

[10] - Lung subtype panel positive subgroup

### Statistical analyses

<b>Statistical analysis title</b>	Analysis of ORR in LSP+ Subgroup
Comparison groups	Investigator's Choice Chemotherapy v Veliparib + Carboplatin + Paclitaxel
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.445 <sup>[11]</sup>
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	0.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.23
upper limit	1.9

Notes:

[11] - Logistic regression adjusted for the covariates of ECOG performance status, investigators' preferred platinum therapy, and gender.

### Secondary: Overall Survival in All Participants

End point title	Overall Survival in All Participants
End point description:	Overall survival is defined as the time from the date that the participant was randomized to the date of the participant's death. Overall survival was estimated using Kaplan-Meier methodology. Participants still alive at the data cut-off date were censored at the date they were last known to be alive.
End point type	Secondary
End point timeframe:	From randomization up to the data cut-off date of 15 July 2019; median follow-up time was 45.4 and 44.6 months in all participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.

<b>End point values</b>	Investigator's Choice Chemotherapy	Veliparib + Carboplatin + Paclitaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	297 <sup>[12]</sup>	298 <sup>[13]</sup>		
Units: monthts				
median (confidence interval 95%)	12.1 (10.0 to 13.7)	12.1 (10.4 to 14.9)		

Notes:

[12] - Intention-to-treat population

[13] - Intention-to-treat population

## Statistical analyses

<b>Statistical analysis title</b>	Analysis of Overall Survival in All Participants
Comparison groups	Investigator's Choice Chemotherapy v Veliparib + Carboplatin + Paclitaxel
Number of subjects included in analysis	595
Analysis specification	Pre-specified
Analysis type	other <sup>[14]</sup>
P-value	= 0.846
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.986
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.827
upper limit	1.176

Notes:

[14] - Log rank test stratified by LSP status, ECOG performance status, investigators' preferred platinum therapy, and gender.

## Secondary: Progression-free Survival in All Participants

End point title	Progression-free Survival in All Participants
-----------------	---

End point description:

Progression-free survival is defined as the time from the date of randomization to the date of disease progression (PD) per RECIST version 1.1 or death (all causes of mortality), whichever occurred first. PD: At least a 20% increase in the size of target lesions, taking as reference the smallest size recorded since the treatment started (Baseline or after) with an absolute increase of at least 5 mm, the appearance of one or more new lesions, or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier methodology. Participants who did not have an event of disease progression or had not died on or before the cut-off date were censored at the date of their last disease progression assessment on or before the cut-off date. Any PD and death occurring > 26 weeks and > 12 weeks after the previous assessment, respectively, were excluded and patients were censored at last assessment before PD or death.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up to the data cut-off date of 15 July 2019; median follow-up time was 45.4 and 44.6 months in all participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.

<b>End point values</b>	Investigator's Choice Chemotherapy	Veliparib + Carboplatin + Paclitaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	297 <sup>[15]</sup>	298 <sup>[16]</sup>		
Units: months				
median (confidence interval 95%)	6.7 (5.6 to 7.2)	5.9 (5.0 to 6.5)		

Notes:

[15] - Intention-to-treat population

[16] - Intention-to-treat population

## Statistical analyses

<b>Statistical analysis title</b>	Analysis of PFS in All Participants
Comparison groups	Investigator's Choice Chemotherapy v Veliparib + Carboplatin + Paclitaxel
Number of subjects included in analysis	595
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.473 <sup>[17]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.035
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.867
upper limit	1.235

Notes:

[17] - Log rank test stratified by LSP status, ECOG performance status, investigators' preferred platinum therapy, and gender.

### Secondary: Objective Response Rate in All Participants

End point title	Objective Response Rate in All Participants
-----------------	---

End point description:

Objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria. Response must have been confirmed at a consecutive assessment 28 days or more after the assessment at which response was first observed.

CR: The disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters, persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, or any new lesions.

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed on Day 1 of Cycles 3 and 5 then every 9 weeks for 1 year or until maintenance therapy was discontinued, then every 12 weeks until radiographic progression or death; median time on follow-up was 6.7 and 5.9 months in each group, respectively.

End point values	Investigator's Choice Chemotherapy	Veliparib + Carboplatin + Paclitaxel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	297 <sup>[18]</sup>	298 <sup>[19]</sup>		
Units: percentage of participants				
number (confidence interval 95%)	29.0 (23.9 to 34.5)	26.2 (21.3 to 31.6)		

Notes:

[18] - Intention-to-treat population

[19] - Intention-to-treat population

### Statistical analyses

<b>Statistical analysis title</b>	Analysis of ORR in All Participants
Comparison groups	Investigator's Choice Chemotherapy v Veliparib + Carboplatin + Paclitaxel

Number of subjects included in analysis	595
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.409 [20]
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.59
upper limit	1.24

Notes:

[20] - Logistic regression adjusted for the covariates of LSP status, ECOG performance status, investigators' preferred platinum therapy, and gender.

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug until 30 days after last dose of study drug (veliparib or investigators' choice of standard chemotherapy); median duration of treatment ranged from 86 to 111 days for each treatment.

Adverse event reporting additional description:

The as-treated subjects population included all participants who received at least 1 dose of study drug (veliparib/investigator's choice of standard chemotherapy).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	21.0

### Reporting groups

Reporting group title	Veliparib + Carboplatin + Paclitaxel
-----------------------	--------------------------------------

Reporting group description:

Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\*min on Day 1 and paclitaxel 200 mg/m<sup>2</sup> on Day 1 of each 21-day cycle for a maximum of 6 cycles.

After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m<sup>2</sup> on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.

Reporting group title	Investigator's Choice Chemotherapy
-----------------------	------------------------------------

Reporting group description:

Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:

- Carboplatin AUC 6 mg/mL\*min + paclitaxel 200 mg/m<sup>2</sup>
- Cisplatin 75 mg/m<sup>2</sup> + pemetrexed 500 mg/m<sup>2</sup>
- Carboplatin AUC 6 or AUC 5 mg/mL\*min + pemetrexed 500 mg/m<sup>2</sup> After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m<sup>2</sup> on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.

Serious adverse events	Veliparib + Carboplatin + Paclitaxel	Investigator's Choice Chemotherapy	
Total subjects affected by serious adverse events			
subjects affected / exposed	121 / 293 (41.30%)	98 / 288 (34.03%)	
number of deaths (all causes)	249	252	
number of deaths resulting from adverse events	24	22	
Vascular disorders			
ANEURYSM			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
AXILLARY VEIN THROMBOSIS			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	



occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DEEP VEIN THROMBOSIS</b>			
subjects affected / exposed	0 / 293 (0.00%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HYPOTENSION</b>			
subjects affected / exposed	2 / 293 (0.68%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HYPOVOLAEMIC SHOCK</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>ORTHOSTATIC HYPOTENSION</b>			
subjects affected / exposed	0 / 293 (0.00%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>VENOUS THROMBOSIS</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
<b>CANCER PAIN</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTRIC CANCER</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>MALIGNANT NEOPLASM PROGRESSION</b>			
subjects affected / exposed	14 / 293 (4.78%)	10 / 288 (3.47%)	

occurrences causally related to treatment / all	0 / 19	0 / 12	
deaths causally related to treatment / all	0 / 8	0 / 4	
<b>MALIGNANT PLEURAL EFFUSION</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>METASTASES TO BONE</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>METASTASES TO CENTRAL NERVOUS SYSTEM</b>			
subjects affected / exposed	4 / 293 (1.37%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>METASTASES TO MENINGES</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PERICARDIAL EFFUSION MALIGNANT</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Immune system disorders</b>			
<b>ANAPHYLACTIC SHOCK</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DRUG HYPERSENSITIVITY</b>			
subjects affected / exposed	3 / 293 (1.02%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>General disorders and administration site conditions</b>			

<b>ASTHENIA</b>			
subjects affected / exposed	1 / 293 (0.34%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CATHETER SITE HAEMORRHAGE</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CHEST PAIN</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DISEASE PROGRESSION</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>FATIGUE</b>			
subjects affected / exposed	0 / 293 (0.00%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GENERAL PHYSICAL HEALTH DETERIORATION</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>MALAISE</b>			
subjects affected / exposed	0 / 293 (0.00%)	3 / 288 (1.04%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>MULTIPLE ORGAN DYSFUNCTION SYNDROME</b>			
subjects affected / exposed	0 / 293 (0.00%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
<b>NON-CARDIAC CHEST PAIN</b>			

subjects affected / exposed	2 / 293 (0.68%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PERIPHERAL SWELLING</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PYREXIA</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>SUDDEN DEATH</b>			
subjects affected / exposed	2 / 293 (0.68%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	2 / 2	0 / 1	
deaths causally related to treatment / all	2 / 2	0 / 1	
<b>SYSTEMIC INFLAMMATORY RESPONSE SYNDROME</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Psychiatric disorders</b>			
<b>CONFUSIONAL STATE</b>			
subjects affected / exposed	1 / 293 (0.34%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DELIRIUM</b>			
subjects affected / exposed	2 / 293 (0.68%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DEPRESSION</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DISORIENTATION</b>			

subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Injury, poisoning and procedural complications</b>			
<b>FALL</b>			
subjects affected / exposed	1 / 293 (0.34%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>FEMORAL NECK FRACTURE</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HEART INJURY</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>HIP FRACTURE</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LUMBAR VERTEBRAL FRACTURE</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>RADIATION OESOPHAGITIS</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>SPINAL COMPRESSION FRACTURE</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Investigations</b>			

C-REACTIVE PROTEIN INCREASED subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
ARTERIOSPASM CORONARY subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATRIAL FIBRILLATION subjects affected / exposed	4 / 293 (1.37%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	1 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATRIAL FLUTTER subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC ARREST subjects affected / exposed	0 / 293 (0.00%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
CARDIAC FAILURE subjects affected / exposed	1 / 293 (0.34%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
CARDIAC FAILURE ACUTE subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
CARDIO-RESPIRATORY ARREST subjects affected / exposed	1 / 293 (0.34%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
CARDIOPULMONARY FAILURE			

subjects affected / exposed	2 / 293 (0.68%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
<b>LEFT VENTRICULAR FAILURE</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PERICARDIAL EFFUSION</b>			
subjects affected / exposed	7 / 293 (2.39%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	1 / 7	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PERICARDITIS</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>SUPRAVENTRICULAR TACHYCARDIA</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory, thoracic and mediastinal disorders</b>			
<b>ACUTE RESPIRATORY FAILURE</b>			
subjects affected / exposed	2 / 293 (0.68%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
<b>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</b>			
subjects affected / exposed	2 / 293 (0.68%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DYSPNOEA</b>			
subjects affected / exposed	8 / 293 (2.73%)	7 / 288 (2.43%)	
occurrences causally related to treatment / all	0 / 8	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DYSPNOEA EXERTIONAL</b>			

subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>HAEMOPTYSIS</b>		
subjects affected / exposed	1 / 293 (0.34%)	3 / 288 (1.04%)
occurrences causally related to treatment / all	1 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
<b>HYPOXIA</b>		
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>ORGANISING PNEUMONIA</b>		
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>PLEURAL EFFUSION</b>		
subjects affected / exposed	5 / 293 (1.71%)	6 / 288 (2.08%)
occurrences causally related to treatment / all	0 / 7	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0
<b>PLEURITIC PAIN</b>		
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>PNEUMONIA ASPIRATION</b>		
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>PNEUMOTHORAX</b>		
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>PRODUCTIVE COUGH</b>		
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)



occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PULMONARY EMBOLISM</b>			
subjects affected / exposed	5 / 293 (1.71%)	6 / 288 (2.08%)	
occurrences causally related to treatment / all	2 / 5	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PULMONARY HAEMORRHAGE</b>			
subjects affected / exposed	0 / 293 (0.00%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>RESPIRATORY DISTRESS</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>RESPIRATORY FAILURE</b>			
subjects affected / exposed	2 / 293 (0.68%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 2	
<b>RHINORRHOEA</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
<b>ANAEMIA</b>			
subjects affected / exposed	7 / 293 (2.39%)	15 / 288 (5.21%)	
occurrences causally related to treatment / all	2 / 8	0 / 17	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>FEBRILE NEUTROPENIA</b>			
subjects affected / exposed	13 / 293 (4.44%)	7 / 288 (2.43%)	
occurrences causally related to treatment / all	9 / 15	0 / 10	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LEUKOPENIA</b>			
subjects affected / exposed	2 / 293 (0.68%)	0 / 288 (0.00%)	
occurrences causally related to	2 / 2	0 / 0	

treatment / all			
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>LYMPHADENITIS</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>NEUTROPENIA</b>			
subjects affected / exposed	6 / 293 (2.05%)	5 / 288 (1.74%)	
occurrences causally related to treatment / all	2 / 9	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PANCYTOPENIA</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>THROMBOCYTOPENIA</b>			
subjects affected / exposed	2 / 293 (0.68%)	6 / 288 (2.08%)	
occurrences causally related to treatment / all	1 / 2	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
<b>CEREBRAL INFARCTION</b>			
subjects affected / exposed	2 / 293 (0.68%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CEREBRAL ISCHAEMIA</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CEREBROVASCULAR ACCIDENT</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>COGNITIVE DISORDER</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	

deaths causally related to treatment / all	0 / 0	0 / 0	
PERIPHERAL SENSORY NEUROPATHY			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SPINAL CORD COMPRESSION			
subjects affected / exposed	1 / 293 (0.34%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
ABDOMINAL PAIN			
subjects affected / exposed	2 / 293 (0.68%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
APHTHOUS ULCER			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ASCITES			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLITIS ISCHAEMIC			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
COLITIS ULCERATIVE			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CONSTIPATION			
subjects affected / exposed	2 / 293 (0.68%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	2 / 2	0 / 1	

deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DIARRHOEA</b>			
subjects affected / exposed	2 / 293 (0.68%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTRITIS</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HAEMATEMESIS</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>INTESTINAL OBSTRUCTION</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>MESENTERIC VEIN THROMBOSIS</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>NAUSEA</b>			
subjects affected / exposed	3 / 293 (1.02%)	3 / 288 (1.04%)	
occurrences causally related to treatment / all	2 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>OESOPHAGEAL STENOSIS</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>OESOPHAGITIS</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

RECTAL HAEMORRHAGE			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
VOMITING			
subjects affected / exposed	6 / 293 (2.05%)	5 / 288 (1.74%)	
occurrences causally related to treatment / all	4 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	1 / 293 (0.34%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
AZOTAEMIA			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMATURIA			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL FAILURE			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL IMPAIRMENT			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY RETENTION			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			

HEPATIC FUNCTION ABNORMAL subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders SUBCUTANEOUS EMPHYSEMA subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders ARTHRALGIA subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BACK PAIN subjects affected / exposed	3 / 293 (1.02%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
BONE PAIN subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCULOSKELETAL CHEST PAIN subjects affected / exposed	1 / 293 (0.34%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUSCULOSKELETAL PAIN subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PAIN IN EXTREMITY subjects affected / exposed	1 / 293 (0.34%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	2 / 293 (0.68%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEHYDRATION			
subjects affected / exposed	0 / 293 (0.00%)	6 / 288 (2.08%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOCALCAEMIA			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPOGLYCAEMIA			
subjects affected / exposed	1 / 293 (0.34%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPONATRAEMIA			
subjects affected / exposed	1 / 293 (0.34%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
TYPE 2 DIABETES MELLITUS			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
ABDOMINAL ABSCESS			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
APPENDICITIS PERFORATED			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	

deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BACTERAEMIA</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>BRONCHITIS</b>			
subjects affected / exposed	1 / 293 (0.34%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CELLULITIS</b>			
subjects affected / exposed	1 / 293 (0.34%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CLOSTRIDIUM DIFFICILE COLITIS</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DEVICE RELATED INFECTION</b>			
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>DIARRHOEA INFECTIOUS</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>EMPHYEMA</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>GASTROENTERITIS</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	



HERPES ZOSTER		
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
INFECTION		
subjects affected / exposed	0 / 293 (0.00%)	2 / 288 (0.69%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
INFLUENZA		
subjects affected / exposed	2 / 293 (0.68%)	0 / 288 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
LOWER RESPIRATORY TRACT INFECTION		
subjects affected / exposed	4 / 293 (1.37%)	1 / 288 (0.35%)
occurrences causally related to treatment / all	4 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1
LUNG INFECTION		
subjects affected / exposed	2 / 293 (0.68%)	0 / 288 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
LYMPHANGITIS		
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
NEUTROPENIC SEPSIS		
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
PERITONSILLAR ABSCESS		
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)
occurrences causally related to treatment / all	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
PNEUMONIA		

subjects affected / exposed	19 / 293 (6.48%)	8 / 288 (2.78%)
occurrences causally related to treatment / all	4 / 26	0 / 9
deaths causally related to treatment / all	0 / 3	0 / 0
<b>PNEUMONIA BACTERIAL</b>		
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>PNEUMONIA PSEUDOMONAL</b>		
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>PSEUDOMONAL SEPSIS</b>		
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>PULMONARY SEPSIS</b>		
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>PYELONEPHRITIS</b>		
subjects affected / exposed	0 / 293 (0.00%)	1 / 288 (0.35%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>RESPIRATORY TRACT INFECTION</b>		
subjects affected / exposed	1 / 293 (0.34%)	1 / 288 (0.35%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
<b>SEPSIS</b>		
subjects affected / exposed	1 / 293 (0.34%)	4 / 288 (1.39%)
occurrences causally related to treatment / all	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 2
<b>SEPTIC SHOCK</b>		
subjects affected / exposed	2 / 293 (0.68%)	1 / 288 (0.35%)

occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
<b>UPPER RESPIRATORY TRACT INFECTION</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>URINARY TRACT INFECTION</b>			
subjects affected / exposed	2 / 293 (0.68%)	2 / 288 (0.69%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>VASCULAR DEVICE INFECTION</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>VIRAL UPPER RESPIRATORY TRACT INFECTION</b>			
subjects affected / exposed	1 / 293 (0.34%)	0 / 288 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Veliparib + Carboplatin + Paclitaxel	Investigator's Choice Chemotherapy	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	275 / 293 (93.86%)	269 / 288 (93.40%)	
<b>Investigations</b>			
<b>WEIGHT DECREASED</b>			
subjects affected / exposed	14 / 293 (4.78%)	24 / 288 (8.33%)	
occurrences (all)	17	25	
<b>Respiratory, thoracic and mediastinal disorders</b>			
<b>COUGH</b>			
subjects affected / exposed	27 / 293 (9.22%)	29 / 288 (10.07%)	
occurrences (all)	32	31	
<b>DYSPNOEA</b>			

subjects affected / exposed occurrences (all)	42 / 293 (14.33%) 46	25 / 288 (8.68%) 30	
HICCUPS subjects affected / exposed occurrences (all)	17 / 293 (5.80%) 27	21 / 288 (7.29%) 29	
OROPHARYNGEAL PAIN subjects affected / exposed occurrences (all)	6 / 293 (2.05%) 8	15 / 288 (5.21%) 16	
Blood and lymphatic system disorders ANAEMIA subjects affected / exposed occurrences (all)	112 / 293 (38.23%) 212	107 / 288 (37.15%) 197	
LEUKOPENIA subjects affected / exposed occurrences (all)	43 / 293 (14.68%) 77	40 / 288 (13.89%) 77	
NEUTROPENIA subjects affected / exposed occurrences (all)	104 / 293 (35.49%) 210	89 / 288 (30.90%) 175	
THROMBOCYTOPENIA subjects affected / exposed occurrences (all)	76 / 293 (25.94%) 155	54 / 288 (18.75%) 102	
Nervous system disorders DIZZINESS subjects affected / exposed occurrences (all)	17 / 293 (5.80%) 17	22 / 288 (7.64%) 25	
DYSGEUSIA subjects affected / exposed occurrences (all)	19 / 293 (6.48%) 20	29 / 288 (10.07%) 33	
PERIPHERAL SENSORY NEUROPATHY subjects affected / exposed occurrences (all)	131 / 293 (44.71%) 195	42 / 288 (14.58%) 51	
General disorders and administration site conditions ASTHENIA subjects affected / exposed occurrences (all)	29 / 293 (9.90%) 58	30 / 288 (10.42%) 50	
FATIGUE			

subjects affected / exposed occurrences (all)	80 / 293 (27.30%) 108	89 / 288 (30.90%) 117	
OEDEMA PERIPHERAL subjects affected / exposed occurrences (all)	13 / 293 (4.44%) 16	24 / 288 (8.33%) 36	
PYREXIA subjects affected / exposed occurrences (all)	15 / 293 (5.12%) 17	16 / 288 (5.56%) 21	
Psychiatric disorders INSOMNIA subjects affected / exposed occurrences (all)	37 / 293 (12.63%) 39	30 / 288 (10.42%) 30	
Gastrointestinal disorders CONSTIPATION subjects affected / exposed occurrences (all)	69 / 293 (23.55%) 81	92 / 288 (31.94%) 113	
DIARRHOEA subjects affected / exposed occurrences (all)	51 / 293 (17.41%) 70	47 / 288 (16.32%) 60	
NAUSEA subjects affected / exposed occurrences (all)	86 / 293 (29.35%) 121	131 / 288 (45.49%) 202	
STOMATITIS subjects affected / exposed occurrences (all)	19 / 293 (6.48%) 24	30 / 288 (10.42%) 32	
VOMITING subjects affected / exposed occurrences (all)	39 / 293 (13.31%) 48	73 / 288 (25.35%) 99	
Skin and subcutaneous tissue disorders ALOPECIA subjects affected / exposed occurrences (all)	137 / 293 (46.76%) 160	34 / 288 (11.81%) 40	
RASH subjects affected / exposed occurrences (all)	13 / 293 (4.44%) 16	25 / 288 (8.68%) 29	
Musculoskeletal and connective tissue disorders			

ARTHRALGIA			
subjects affected / exposed	39 / 293 (13.31%)	26 / 288 (9.03%)	
occurrences (all)	45	35	
BACK PAIN			
subjects affected / exposed	17 / 293 (5.80%)	22 / 288 (7.64%)	
occurrences (all)	21	24	
BONE PAIN			
subjects affected / exposed	15 / 293 (5.12%)	9 / 288 (3.13%)	
occurrences (all)	21	13	
MYALGIA			
subjects affected / exposed	38 / 293 (12.97%)	17 / 288 (5.90%)	
occurrences (all)	50	22	
PAIN IN EXTREMITY			
subjects affected / exposed	15 / 293 (5.12%)	15 / 288 (5.21%)	
occurrences (all)	17	19	
Metabolism and nutrition disorders			
DECREASED APPETITE			
subjects affected / exposed	63 / 293 (21.50%)	79 / 288 (27.43%)	
occurrences (all)	79	109	
HYPOMAGNESAEMIA			
subjects affected / exposed	21 / 293 (7.17%)	16 / 288 (5.56%)	
occurrences (all)	22	19	
HYPERGLYCAEMIA			
subjects affected / exposed	24 / 293 (8.19%)	11 / 288 (3.82%)	
occurrences (all)	24	15	
HYPONATRAEMIA			
subjects affected / exposed	16 / 293 (5.46%)	12 / 288 (4.17%)	
occurrences (all)	18	14	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 October 2014	Added language to include details on pregnancy testing and to clarify drug labeling
10 December 2014	Changed study phase from Phase 2 to Phase 3 throughout protocol to conform to request by US Food and Drug Administration (FDA); revised investigator's choice stratification factor to preferred platinum doublet chemotherapy to assure balance of subjects suitable for C/P across arms; revised eligibility criteria to reflect exclusion of subjects who have received prior cytotoxic chemotherapy chemoradiotherapy for NSCLC, except adjuvant or neoadjuvant therapy > 12 months prior to C1D-2 for clarification; expanded screening period from 21 to 28 days to reduce number of screen failures that may have occurred due to screening test delays; included Japan-specific protocol language requirements to include facilitation of Japanese sites.
17 July 2015	Clarified and changed the reference day defining baseline assessment windows throughout; added language regarding starting doses for subjects randomized to the investigator's choice arm; specified that 24 hour urine collection or radioisotope methods were allowed for creatinine clearance/glomerular filtration rate (GFR) measurement; specified washout periods for allowed prior NSCLC treatment in Exclusion Criterion 6; added Japan-specific requirements throughout.
09 May 2018	The patient population for the primary endpoint of OS was amended from current smokers to subjects who were positive for the LSP signature; subjects who were LSP positive were to also replace the current smoker population for other key efficacy analyses; updated number of subjects to be enrolled from approximately 525 to 595 subjects.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported